

Cruciferous Vegetables-Based Isothiocyanate Compounds as Novel Epigenetic Modulators in Human Malignant Melanoma


Mihalis Panagiotidis, PhD Senior Scientist & Department Head

Department of Electron Microscopy & Molecular Pathology, Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus



General Features of ITCs


- Cruciferous vegetables contain vitamins, minerals, other nutrients, and chemicals known as glucosinolates
- Glucosinolates break down into several biologically active compounds (e.g. ITCs) which are being studied for possible anticancer effects
- Some of them have shown anti-cancer effects in cells and animals but studies in humans have been inconclusive)



Myrosinase released by chopping or chewing cruciferous vegetables breaks down glucosinolates to isothiocyanates, releasing glucose and sulfate in the process. "R" designates side chains of other elements in the molecule. *C=carbon, S=sulfur, N=nitrogen*



Major Dietary ITCs Of Interest




Mitsiogianni et al. Pharmacol Ther, 190: 187-201, 2018

ITC	GL-ITC Precursor	Food Source	Total Conc. (mg/100g)	
SFN	Glucoraphanin	Broccoli Brussel sprouts Cabbage	61 236 78	
IBN	Glucoiberin	Cabbage Broccoli	229 70	
BITC	Glucotropaeolin	Cabbage Garden cress	78 392	
PEITC	Gluconasturtiin	Watercress	94	
AITC	Sinigrin	Broccoli Brussel sprouts Cabbage Mustard greens	61 236 78 282	



Modulation Of Various Cellular Pathways By ITCs




Mitsiogianni et al. Antioxidants, 8(4): 106, 2019

- Inhibition of Phase I and induction of Phase II enzymes
- Induction of cell cycle arrest (Mantso et al., Anticancer Research 36: 6303-6309, 2016)
- Promotion of apoptosis (Mantso et al., Anticancer Research, 2019, in press)
- Modulation of epigenetic response
 - HDAC inhibition
 - **DNMTs** inhibition
 - MicroRNA modulation
- Anti-angiogenic and anti-metastatic properties




In Vitro Model of HaCaT cells



cells



Toxicity Profile of AITC




Mitsiogianni et al. Eur J Nutr, 59(2): 557-669, 2020



Toxicity Profile of SFN, IBN, BITC & PEITC

		A375	НаСаТ	A431	VMM1	Hs294T	B16-F10
SFN	EC50 _{24h} (µM)	15.7 ± 0.15	21.6 ± 2.00	46.05 ± 12.04	35.3 ± 11.7	8.97 ± 0.8	20.88 ± 2.00
	EC50 _{48h} (μM)	15.6 ± 2.4	23.3 ± 2.4	20.87 ± 0.96	24.11 ± 1.3	6.5 ± 0.12	15.37 ± 0.5
IBN -	EC50 _{24h} (μM)	8.3 ± 1.06	23.56 ± 4.4	48.51 ± 16.1	50.5 ± 9.5	11.3 ± 2.6	21.09 ± 0.9
	EC50 _{48h} (μM)	8.6 ± 0.7	23.6 ± 1.9	15.26 ± 1.8	23.05 ± 1.2	8.96 ± 1.6	19.97 ± 5.4




Mitsiogianni et al. Eur J Nutr, 2020 (in press)



Overview Of Cancer Epigenetics

Me



modifications which play essential roles in gene expression regulation and disease processes

Methylated


Unmethylated

The Concept of Epigenetic Diet: How What We Eat Could Affect Tags on Our DNA





Dietary Inhibitors of DNA Methyltransferases




- Hypermethylation of CpG dinucleotides, by DNMTs, usually results in transcriptional gene silencing and gene inactivation
- Several bioactive compounds act as dietary inhibitors of DNA methyltransferases and also alter gene expression via epigenetic mechanisms

Hardy, TM & Tollefsbol, TO. Epigenomics, 3(4): 503-518, 2011



Dietary Modifiers of Histones



Bioactive compounds can alter HATs and HDACs by causing conformational changes in chromatin structure thereby altering gene expression

HATs induce a relaxed chromatin state indicative of gene expression whereas chromatin in its closed state is indicative of gene silencing and repression

Hardy, TM & Tollefsbol, TO. Epigenomics, 3(4): 503-518, 2011



DIETARY COMPOUNDS

EC, ECG, EGC and EGCG

Resveratrol

Curcumin

Genistein

Isothiocyanates, sulforaphane Selenium

Allyl mercaptan, organosulfur compounds Folate

Alcohol

FOOD SOURCES

Green tea

Grapes, peanuts, mulberries, cranberries, blueberries Tumeric, curry

Soybeans, fava beans

Broccoli, cabbage, kale, watercress Brazilian nuts, chicken, game meat, beef Garlic

Beans, grains, fortified breakfast cereals, pastas, green vegetables Alcoholic beverages

EPIGENETIC FUNCTIONS

DNMT and HAT inhibitor, modulates miRNA DNMT and HDAC inhibitor

DNMT inhibitor and miRNA modulator

DNMT and HDAC inhibitor, enhances HATs, modulates miRNA DNMT and HDAC inhibitor DNMT and HDAC inhibitor

HDAC inhibitor


Deficiencies alter DNA methylation patterns

High consumption increases promoter hypermethylation

Hardy, TM & Tollefsbol, TO. Epigenomics, 3(4): 503-518, 2011



Histone Modifications Capable of Altering Gene Expression




- Histone N-terminal tail
 has a crucial role in
 modulating nucleosome
 structure and function.
- Various modifications on different residues of histone tail are shown
- S, T, K and R represent
 Serine, Threonine, Lysine
 & Arginine respectively


Biswas, S & Rao, CM. Pharmacol Ther, 173: 118-134, 2017



AITC Induces The Epigenetic Response




Mitsiogianni et al. Eur J Nutr, 59(2): 557-669, 2020





Inhibition Of DNMT1A Potentiates the Effect of AITC



Pre-treatment with Decitabine, for 24 hrs, followed by cotreatment with AITC and Decitabine for 48 hrs




Image courtesy of David Steensma, MD


If a tumor-suppressor gene is not being transcribed in a malignant cell, treating with a DNA-methyltransferase inhibitor can open the chromatin and change the level at which transcription is occurring, thereby killing the malignant cell. This is the hypothesis for how Azacytidine and Decitabine are working in MDS


Mitsiogianni et al. Eur J Nutr, 59(2): 557-669, 2020

www.medscape.org



Inhibition Of HDAC Potentiates the Effect of AITC






Pre-treatment with Panobinostat, for 24 hrs, followed by co-treatment with AITC and Panobinostat for 48 hrs

> Mitsiogianni et al. Eur J Nutr, 59(2): 557-669, 2020



Inhibition Of HAT Potentiates the Effect of AITC




www.researchgate.net


Mitsiogianni et al. Eur J Nutr, 59(2): 557-669, 2020



Epigenetic Therapy & HDACi




Modelling of ITCs as HDAC inhibitors by computer-aided drug design



Mitsiogianni et al. Eur J Nutr, 59(2): 557-669, 2020 Mitsiogianni et al. Eur J Nutr, 2020 (in press)

Rajendran et al. Crit Rev Biochem Mol Biol, 46(3): 181-199, 2011



Epigenetic Therapy & HDACi

Invest New Drugs. 2012 Dec;30(6):2303-2317.

Phase 1 clinical trial of the novel proteasome inhibitor Marizomib with the histone deacetylase inhibitor Vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.

Br J Cancer. 2009 Oct 6;101(7):1044-1050.

Phase I trial of Vorinostat and Doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.

Melanoma Res. 2008 Aug;18(4):274-27

Multi-center phase II trial of the histone deacetylase inhibitor Entinostat in pre-treated metastatic melanoma.

Clin Cancer Res. 2009 Apr 1;15(7):2479-2487.

Potentiation of a topoisomerase I inhibitor, Karenitecin, by the histone deacetylase inhibitor Valproic acid in melanoma: translational and phase I/II clinical trial.

Br J Cancer. 2009 Jan 13;100(1):28-36.

A phase I-II study of the histone deacetylase inhibitor Valproic acid plus Dacarbazine and Interferon- α in patients with advanced melanoma.

Mottamal et al. Molecules, 20(3): 3898-941, 2015

